Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Rigin vs Syn-Ake

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Rigin and Syn-Ake share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Syn-Ake has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Syn-Ake's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Rigin

Cosmetic Clinical Studies

Syn-Ake

Cosmetic Clinical Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: minimal. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

Rigin Syn-Ake
Class Cosmetic lipopeptide (anti-inflammatory) Cosmetic peptide (snake-venom inspired)
Drug class Dermatologic Dermatologic
Mechanism Suppresses IL-6 secretion by fibroblasts; reduces inflammaging Waglerin-1 mimic; antagonizes nicotinic ACh receptor at muscle
Route Topical Topical
Half-life Topical Topical
Dosage (research) Topical 2-4% Topical 4%
Evidence tier Cosmetic Clinical Studies Cosmetic Clinical Studies
Research depth 31 indexed (PubMed 15 · CT 0 · EPMC 16) 5 indexed (PubMed 2 · CT 0 · EPMC 3)
Availability Cosmetic Cosmetic
Reported risks Minimal Minimal

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Rigin or Syn-Ake?

Rigin and Syn-Ake share the cosmetic class and carry roughly equivalent evidence (Cosmetic Clinical Studies / Cosmetic Clinical Studies). On the catalogued data layer Syn-Ake has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Syn-Ake's evidence base is currently denser.

What is the difference between Rigin and Syn-Ake?

Rigin is classed as Cosmetic lipopeptide (anti-inflammatory); Syn-Ake is classed as Cosmetic peptide (snake-venom inspired). Reported mechanism: Rigin, Suppresses IL-6 secretion by fibroblasts; reduces inflammaging; Syn-Ake, Waglerin-1 mimic; antagonizes nicotinic ACh receptor at muscle. Reported half-life: Rigin, Topical; Syn-Ake, Topical. Routes in published studies: Rigin, Topical; Syn-Ake, Topical.

Which has stronger evidence, Rigin or Syn-Ake?

Rigin and Syn-Ake sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Rigin is graded Cosmetic Clinical Studies, with 2 cited sources on its reference page and 31 indexed studies. Syn-Ake is graded Cosmetic Clinical Studies, with 3 cited sources on its reference page and 5 indexed studies.

Which is more accessible, Rigin or Syn-Ake?

Neither Rigin nor Syn-Ake is an FDA-approved drug. Catalog status: Rigin, Cosmetic; Syn-Ake, Cosmetic.

Are Rigin and Syn-Ake ever combined?

Rigin and Syn-Ake appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…